2,893,009 Shares in Metsera Inc. $MTSR Acquired by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. has invested approximately $78.75 million in Metsera Inc., acquiring 2,893,009 shares, which represents 2.75% ownership as of their most recent SEC filing.
• Several other institutional investors also established positions in Metsera, including Alphabet Inc. with an investment of $135 million, and Jennison Associates LLC with $9.67 million.
• Metsera's stock has a consensus rating of "Buy" from five analysts, with a target price ranging around $55.00 to $65.00.

T. Rowe Price Investment Management Inc. bought a new position in Metsera Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,893,009 shares of the company's stock, valued at approximately $78,748,000. T. Rowe Price Investment Management Inc. owned about 2.75% of Metsera at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Alphabet Inc. purchased a new stake in Metsera in the first quarter worth about $135,059,000. Jennison Associates LLC purchased a new stake in Metsera in the first quarter worth about $9,679,000. TD Asset Management Inc purchased a new stake in Metsera in the first quarter worth about $2,091,000. Wellington Management Group LLP purchased a new stake in Metsera in the first quarter worth about $65,382,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in Metsera in the first quarter worth about $13,111,000.

Wall Street Analysts Forecast Growth

Several brokerages have commented on MTSR. Wells Fargo & Company began coverage on shares of Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price objective for the company. Guggenheim raised their price objective on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $55.00.

Metsera Price Performance

Shares of MTSR stock traded up $1.35 during trading hours on Wednesday, hitting $34.54. 1,288,161 shares of the company's stock traded hands, compared to its average volume of 996,106. The stock's fifty day simple moving average is $33.58 and its two-hundred day simple moving average is $28.39. Metsera Inc. has a 12-month low of $12.30 and a 12-month high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Metsera Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.